Company Logo
Key opportunities in the Mental Health Clinical Trials market include leveraging digital-first study models to reduce participation burden, maximizing venture funding in psychedelic therapies, and harnessing AI-enabled platforms for operational efficiency. Geographic expansion and prioritized regulatory pathways further propel market growth.
Dublin, Jan. 29, 2026 (GLOBE NEWSWIRE) — The “Mental Health Clinical Trials – Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)” has been added to ResearchAndMarkets.com’s offering.
The Mental Health Clinical Trials market is projected to expand from USD 3.56 billion in 2025 to USD 3.85 billion in 2026, eventually reaching USD 5.65 billion by 2031, exhibiting a CAGR of 8.02% from 2026 to 2031. This growth is underpinned by increasing psychiatric disorder prevalence, surging digital-first study models, and substantial venture funding for psychedelic therapies. Sponsor budgets are bolstered by late-stage pipeline maturation, while regulatory bodies accelerate neurotherapeutic approvals.
Remote assessments facilitate broader demographic engagement, though high dropout rates persist as a cost challenge. Competition heightens as AI-enabled platforms present leaner models that rival established contract research organizations.
Global Market Trends and Insights Rising Prevalence of Mental Health Conditions
With over 970 million people globally affected by psychiatric disorders, the economic impact of untreated cases reaches USD 1 trillion annually. Heightened post-pandemic awareness has accelerated study enrollments, notably with depression study enrollments increasing by 34% compared to 2019. Sponsors are scaling Phase II and III programs for treatment-resistant cohorts, supported by breakthrough designations that expedite regulatory cycles.
Increasing Pharma & Biotech R&D Investment
Neuropsychiatric R&D spending is forecasted to reach USD 15.2 billion in 2024, a 28% increase year-over-year. Major mergers like the USD 14.6 billion acquisition of Intra-Cellular Therapies signal confidence in late-stage assets. Biotech exploration into AMPA modulation, glutamate pathways, and precision-genetic strategies necessitates extended observation windows, sustained by robust funding flows. Venture capitalists invested USD 2.4 billion into mental-health startups, prominently those focusing on psychedelics.
Challenges in Developing Regions
Surveys across Ghana, Kenya, and South Africa reveal a 68% unawareness rate of depression symptoms among respondents. Cultural stigma limits trial participation and traditional healing practices often conflict with Western methodologies. Infrastructure deficits and complex consent processes impede operational timelines.
Additional Market Drivers and Restraints:
Adoption of Decentralized & Digital Trial Models
Growing Venture Capital Funding for Psychedelic-Assisted Therapies
High Drop-Out Rates due to Prolonged Therapy Timelines
Segment Analysis
In 2025, interventional trials constituted 71.12% of the market, highlighting a preference for controlled efficacy testing to expedite product approval. While observational approaches represent a smaller market share, their growth rate is notable as payers and regulators prioritize real-world evidence. Digital biomarkers are increasingly utilized in observational studies to capture continuous data, enhancing post-marketing safety insights.
Phase III trials commanded 35.45% of the market share in 2025, signifying the maturity of psychiatric pipelines. Phase II segment expansion continues, with a CAGR of 10.74%, driven by adaptive designs incorporating digital endpoints for improved decision-making.
Geographical Insights
In 2025, North America captured 43.18% market share, driven by FDA designations for psychedelic molecules and digital therapeutics, alongside Medicare reimbursement initiatives. Europe benefits from EMA harmonization and public health enhancements, while Asia-Pacific is marked by a notable 13.38% CAGR due to regulatory streamlining and infrastructure growth.
A selection of companies mentioned in this report includes, but is not limited to:
IQVIA Inc.
ICON plc
Parexel International Corp.
Thermo Fisher Scientific Inc. (PPD)
Syneos Health
Medpace Holdings Inc.
Fortrea Holdings Inc.
Altasciences
Caidya
Lindus Health
Worldwide Clinical Trials
Charles River Laboratories
PSI CRO
WCG Clinical
CTI Clinical Trial & Consulting
Pharmaron
ClinChoice
Covance (legacy)
ProTrials Research
Novotech
For more information about this report visit https://www.researchandmarkets.com/r/o1w9yf
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood,Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
